Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Equity (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Return on Equity for 9 consecutive years, with 0.0% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 46.0% to 0.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.0% through Dec 2025, down 46.0% year-over-year, with the annual reading at 0.0% for FY2025, 54.0% down from the prior year.
  • Return on Equity hit 0.0% in Q4 2025 for Protagonist Therapeutics, down from 0.07% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.46% in Q4 2024 to a low of 0.65% in Q1 2023.
  • Historically, Return on Equity has averaged 0.08% across 5 years, with a median of 0.01% in 2022.
  • Biggest five-year swings in Return on Equity: tumbled -66bps in 2023 and later soared 101bps in 2024.
  • Year by year, Return on Equity stood at 0.0% in 2021, then crashed by -71063bps to 0.55% in 2022, then surged by 55bps to 0.25% in 2023, then surged by 284bps to 0.46% in 2024, then plummeted by -100bps to 0.0% in 2025.
  • Business Quant data shows Return on Equity for PTGX at 0.0% in Q4 2025, 0.07% in Q3 2025, and 0.08% in Q2 2025.